Protocols: Valeant sheds assets, but falls short on consensus; What if voters got a chance to weigh in on your trial?
Valeant CEO Michael Pearson wheeled and dealed his way into a biopharma catastrophe. And now his successor, Joseph Papa, is trying to wheel and deal his way out. The company’s Q2 review included plans to follow up on recent asset sales to help pay off debt. But Valeant also failed to perform according to consensus estimates, raising some fresh concerns about the company. Valeant’s shares are down 90% off their 12-month peak.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.